- Comprehensive alliance forged for joint drug development and clinical trials

- To ensure mutual cooperation, agreement signed for mutual exercise of Dong-A’s voting rights



Dong-A Pharmaceutical (CEO and President: KIM Won-Bae) is gearing up to advance more deeply into the
global market with new drugs developed through its improved R&D.



On March 30, 2009, Dong-A Pharmaceutical announced that the company had agreed on a strategic alliance
with Japan’s Otsuka Pharmaceuticals. The agreement entails joint development of drugs, cooperation in
conducting clinical trials, and cooperation in other accompanying tasks. This move implies Dong-A’s refusal to
be complacent and remain merely number one in Korea, but its determination to pioneer new frontiers by joining
hands with overseas networks to become a global leader in the pharmaceutical industry.



Dong-A possesses excellent new drug development capabilities and high added-value bio drugs, and Otsuka
of Japan boasts world-class clinical trial capabilities based on a global clinical trial network. The two
companies will develop globally competitive new drugs together. They plan to realize strategic synergies by
carrying out clinical trials in accordance with global standards from the very first stages of drug development—
from the derivation of new drug candidates —to effectively make forays into the global market.



“Dong-A and Otsuka already have strong mutual trust as a result of their founding of Dong-A Otsuka, a joint
venture for the beverage business in Korea, and forging of an R&D alliance,” said President Kim of Dong-A
Pharmaceutical, adding, “We expect that the two companies will succeed in the world-wide drug development
contest by building on their close cooperative relationship in R&D, thereby raising their global
competitiveness.”



The Japanese drug company holds 864,362 shares of Dong-A stock, or an 8.27 % stake.





Dong-A Pharmaceutical, one of the Korea’s leading research-based pharmaceutical and
healthcare
companies, is committed to working for a better tomorrow by following its core value of integrity, excellence and
respect for humanity. Dong-A Pharmaceutical has kept its No. 1 position in the Korean pharmaceutical market
since 1967 with its Zydena(erectile dysfunction treatment), Stillen(gastritis treatment), Bacchus(refreshing
tonic) and other 120 products. For further information, please visit www.donga-pharm.com